Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis-Reference-Cited by-同舟云学术

Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis

Published:2018-12-20 Issue:3 Volume:62 Page:1180-1202
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Thomas Michael G.¹,De Rycker Manu¹^ORCID,Ajakane Myriam²,Albrecht Sébastian¹,Álvarez-Pedraglio Ana Isabel³,Boesche Markus²,Brand Stephen¹,Campbell Lorna¹,Cantizani-Perez Juan³,Cleghorn Laura A.T.¹,Copley Royston C.B.⁴,Crouch Sabrinia D.³,Daugan Alain⁵,Drewes Gerard²,Ferrer Santiago³,Ghidelli-Disse Sonja²,Gonzalez Silvia³,Gresham Stephanie L.⁶,Hill Alan P.⁴,Hindley Sean J.⁴,Lowe Rhiannon M.⁶,MacKenzie Claire J.¹,MacLean Lorna¹,Manthri Sujatha¹,Martin Franck⁵,Miguel-Siles Juan³,Nguyen Van Loc⁵,Norval Suzanne¹,Osuna-Cabello Maria¹,Woodland Andrew¹,Patterson Stephen¹,Pena Imanol³,Quesada-Campos Maria Teresa³,Reid Iain H.⁴,Revill Charlotte¹,Riley Jennifer¹,Ruiz-Gomez Jose Ramon³,Shishikura Yoko¹,Simeons Frederick R.C.¹,Smith Alasdair¹,Smith Victoria C.¹,Spinks Daniel¹,Stojanovski Laste¹,Thomas John¹,Thompson Stephen¹,Underwood Tim⁴,Gray David W.¹,Fiandor Jose M.³,Gilbert Ian H.¹^ORCID,Wyatt Paul G.¹^ORCID,Read Kevin D.¹^ORCID,Miles Timothy J.³^ORCID

Affiliation:

1. Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

2. Cellzome GmbH, A GlaxoSmithKline Company, Meyerhofstrasse 1, 69117 Heidelberg, Germany

3. Global Health R&D, GlaxoSmithKline, Calle Severo Ochoa, 2, 28760 Tres Cantos, Madrid Spain

4. Platform Technology & Science, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, U.K.

5. Centre de Recherche, GlaxoSmithKline, Les Ulis, 25,27 Avenue du Québec, 91140 Villebon sur Yvette France

6. Platform Technology & Science, GlaxoSmithKline, David Jack Centre for R&D, Park Road, Ware, Hertfordshire SG12 0DP, U.K.

Funder

Wellcome Trust

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b01218

Reference47 articles.

1. World Health Organization (WHO) List of Neglected Tropical Diseases; World Health Organization: Geneva, 2018; http://www.who.int/neglected_diseases/diseases/en/ (accessed Aug 2, 2018).

2. Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need

3. World Health Organization (WHO) Leishmaniasis Fact Sheet; World Health Organization: Geneva, 2018; http://www.who.int/mediacentre/factsheets/fs375/en/ (accessed Aug 2, 2018).

4. Treatment of visceral leishmaniasis

5. Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis in India After a Decade of Use

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review on potential therapeutic targets for the treatment of leishmaniasis;Parasitology International;2024-06

2. Discovery of 1,3,4-Oxadiazole Derivatives as Broad-Spectrum Antiparasitic Agents;ACS Infectious Diseases;2024-05-08

3. Experimental structure based drug design (SBDD) applications for anti‐leishmanial drugs: A paradigm shift?;Medicinal Research Reviews;2023-12-24

4. Correction to “Bespoke Drug Discovery Training for Low-Middle Income Countries”;ACS Medicinal Chemistry Letters;2023-10-05

5. Molecular-level strategic goals and repressors in Leishmaniasis – Integrated data to accelerate target-based heterocyclic scaffolds;European Journal of Medicinal Chemistry;2023-09